PDS Biotechnology Corp (EU6)

8.254
-0.252(-2.96%)
  • Volume:
    0
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    8.254 - 8.254
  • Type:Equity
  • Market:Germany
  • ISIN:US70465T1079
  • WKN:A2PF3F

EU6 Overview

Prev. Close
8.506
Day's Range
8.254-8.254
Revenue
-
Open
8.254
52 wk Range
1.58-14.485
EPS
-26.25
Volume
0
Market Cap
258.98M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
162
P/E Ratio
-
Beta
3.7
1-Year Change
377.11%
Shares Outstanding
28,435,067
Next Earnings Date
Apr 01, 2022
What is your sentiment on PDS Biotechnology Corp?
or
Market is currently closed. Voting is open during market hours.

PDS Biotechnology Corp Company Profile

Employees
15

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • Researchers in Brazil warn that corona recoverers may re-infect the Brazilian variant. According to the study, the antibodies in the blood of recoverers infected with previous corona strains had a 6-fold reduced ability to neutralize the Brazilian strain.
    1
    • This company has little open news, do you know what they have in the pipe-line?
      0
      • It's back! This is going to the moon and beyond soon. Get in while you can.
        0
        • You better have a great earnings report. Real shady offering your stock at a lower price than listed. I'd sell immediately if I wouldn't lose so much money right now.
          0
          • Well ***happened today? It's up when the market is down and down when the market is up
            0
            • Got in at 4.24 today. Has potential to shoot high. Going to be a long term hold hopefully with steady growth.
              0
              • Anyone who is experienced have any thoughts for PDSB next week? Im in at 3.86
                0
                • I'm ready for the $2.00 movement!
                  0
                  • Finally some movement.. Lets go $2
                    0
                    • Yea! Hoping for $2 I have 2K shares
                      0
                      • Lol
                        1
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.